Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Dec 17, 2023 3:28pm
87 Views
Post# 35788918

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2023

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2023Yes bluemoons20 the website is next to useless.  i saw that coming a couple of years ago when they began using Twitter (X) to make announcements then eventually posting them on there website.  The website is totally outdated except for a few alterations from time to time.

For the share count by calculation the insiders (12) own:
40,750,000 (approx) which accounts for 63%. If you extend that to 100% it represents 65,662,000 total shares outstanding at the moment.  When you add the potential warrants and options you add approx. 10,000,000.
Those 12 individuals and companies control the destiny of this company.  You can bet they know exactly what is going on presently.

I think it boils down to two options: either selling parts or all of the company or taking the company private.

What pi--es me off is the rest of are being kept in the dark.  
<< Previous
Bullboard Posts
Next >>